2. CardioNXT’s RADAR Clinical Trial Addresses Unmet
AF Patient Need
A pioneering cardiologist in the area of atrial fibrillation (AF) care, Sanjiv M. Narayan, MD, PhD,
has a research focus on cardiac electrophysiology at Stanford University and previously at the
University of California in San Diego. He successfully developed the first system to map AF drivers
(the FIRM, Focal Impulse and Rotor Modulation platform), which combines computational analysis
and panoramic mapping in pinpointing exact AF electrical sources within heart tissue. The
accuracy of this work has been validated by optical mapping in human hearts. Dr. Sanjiv M.
Narayan’s work has led to several growth companies in the AF treatment sphere, including
CardioNXT.
3. CardioNXT’s RADAR Clinical Trial Addresses Unmet
AF Patient Need
CardioNXT is developing a product platform that will provide an improved understanding of AF and
other cardiac arrhythmias, and enable targeted therapies to be delivered to impacted heart regions.
Committed to reducing treatment costs, CardioNXT has an aim of enabling global adoption in
underserved emerging markets.
4. CardioNXT’s RADAR Clinical Trial Addresses Unmet
AF Patient Need
In 2018, CardioNXT launched the fully enrolled clinical trial Real-time electrogram Analysis for
Drivers of Atrial fibRillation (RADAR). Involving the participation of 65 individuals, the study
focuses on patients being treated for persistent and long-standing persistent atrial fibrillation.
5. CardioNXT’s RADAR Clinical Trial Addresses Unmet
AF Patient Need
Within the scope of the trial, a new high resolution contact mapping technology is being tested for
efficacy in generating a heart image that cardiac electrophysiologists can easily make use of in
tailoring therapies for patients. As described by the director of Massachusetts General Hospital’s
AF program, the RADAR trial addresses a cardiac electrophysiology need that is unmet at present.